胰腺腺癌生存模式的演变:一个23年后期的观察分析
Tiago Cordeiro Felismino1, Diego Rodrigues2, Angelo Brito1
1Department of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.
Journal of gastrointestinal oncology
|July 17, 2025
概括
引入FOLFIRINOX化疗显著改善了胰腺腺癌 (PA) 患者的生存率. 这项研究显示,FOLFIRINOX后的平均整体存活率翻了一番,而5年存活率几乎翻了三倍.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 临床试验 临床试验
背景情况:
- 胰腺腺癌 (PA) 是一种高度致命的恶性瘤,在历史上治疗选择有限.
- 随着FOLFIRINOX和nab-paclitaxel加上gemcitabine的出现,已改善了晚期PA的治疗结果.
- 这项研究检查了PA的23年生存趋势,比较了FOLFIRINOX采用前后的结果.
研究的目的:
- 在巴西癌症中心分析胰腺腺癌 (PA) 的23年生存趋势.
- 为了比较PA患者在 (2000-2011年) 之前和 (2012-2023年) 引入FOLFIRINOX后的整体生存率.
- 评估随着时间的推移对PA临床病理特征和治疗方式的变化.
主要方法:
- 在2000年至2023年期间诊断和治疗的1,078名PA患者的回顾性分析.
- 两个12年期的比较:第1期 (FOLFIRINOX前) 和第2期 (FOLFIRINOX后).
- 评估整体存活率,临床病理学特征和治疗方式.
主要成果:
- 在FOLFIRINOX引入后,PA患者的平均整体存活期 (mOS) 从7.29个月提高到13.24个月 (P<0.001).
- 五年生存率从5.2%上升到14.3% (P<0.001). 这也使得患者的死亡率从5.2%上升到14.3%.
- 在早期 (I-II) 和第四阶段的PA中观察到mOS的显著改善,而第三阶段的结果显示没有差异.
结论:
- 加入FOLFIRINOX导致胰腺腺癌患者的生存率大幅改善.
- 治疗的进步对PA护理的不断变化的景观产生了积极的影响.
- 长期生存的好处是显而易见的,特别是在晚期疾病.
相关概念视频
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:53Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
01:21Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456